Literature DB >> 26121211

Cathelicidin LL-37 Induces Semaphorin 3A Expression in Human Epidermal Keratinocytes: Implications for Possible Application to Pruritus.

Yoshie Umehara1, Yayoi Kamata1, Mitsutoshi Tominaga1, François Niyonsaba2, Hideoki Ogawa3, Kenji Takamori4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26121211     DOI： 10.1038/jid.2015.243

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  15 in total

1.  Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis.

Authors:  M Tominaga; H Ogawa; K Takamori
Journal:  Br J Dermatol       Date:  2008-01-30       Impact factor: 9.302

Review 2.  Antimicrobial peptides and the skin immune defense system.

Authors:  Jürgen Schauber; Richard L Gallo
Journal:  J Allergy Clin Immunol       Date:  2008-04-25       Impact factor: 10.793

3.  Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis.

Authors:  Osamu Negi; Mitsutoshi Tominaga; Suhandy Tengara; Atsuko Kamo; Kenichi Taneda; Yasushi Suga; Hideoki Ogawa; Kenji Takamori
Journal:  J Dermatol Sci       Date:  2012-01-21       Impact factor: 4.563

4.  Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells.

Authors:  F Niyonsaba; A Someya; M Hirata; H Ogawa; I Nagaoka
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

5.  Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch.

Authors:  Kenichi Taneda; Mitsutoshi Tominaga; Osamu Negi; Suhandy Tengara; Atsuko Kamo; Hideoki Ogawa; Kenji Takamori
Journal:  Br J Dermatol       Date:  2011-08       Impact factor: 9.302

6.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis.

Authors:  Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

7.  Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells.

Authors:  François Niyonsaba; Hiroko Ushio; Mutsuko Hara; Hidenori Yokoi; Mitsutoshi Tominaga; Kenji Takamori; Naoki Kajiwara; Hirohisa Saito; Isao Nagaoka; Hideoki Ogawa; Ko Okumura
Journal:  J Immunol       Date:  2010-02-26       Impact factor: 5.422

8.  Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model.

Authors:  Junko Yamaguchi; Fumio Nakamura; Michiko Aihara; Naoya Yamashita; Hiroshi Usui; Tomonobu Hida; Kohtaro Takei; Yoji Nagashima; Zenro Ikezawa; Yoshio Goshima
Journal:  J Invest Dermatol       Date:  2008-07-10       Impact factor: 8.551

Review 9.  Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications.

Authors:  Mitsutoshi Tominaga; Kenji Takamori
Journal:  J Dermatol       Date:  2014-03       Impact factor: 4.005

Review 10.  Mediators of pruritus in psoriasis.

Authors:  Adam Reich; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711
View more
  6 in total

1.  A single amino acid in MRGPRX2 necessary for binding and activation by pruritogens.

Authors:  Vemuri B Reddy; Thomas A Graham; Ehsan Azimi; Ethan A Lerner
Journal:  J Allergy Clin Immunol       Date:  2017-07-06       Impact factor: 10.793

2.  Candidalysin, a Virulence Factor of Candida albicans, Stimulates Mast Cells by Mediating Cross-Talk Between Signaling Pathways Activated by the Dectin-1 Receptor and MAPKs.

Authors:  Pu Song; Ge Peng; Hainan Yue; Takasuke Ogawa; Shigaku Ikeda; Ko Okumura; Hideoki Ogawa; François Niyonsaba
Journal:  J Clin Immunol       Date:  2022-04-14       Impact factor: 8.542

Review 3.  Keratinocytes: innate immune cells in atopic dermatitis.

Authors:  P Chieosilapatham; C Kiatsurayanon; Y Umehara; J V Trujillo-Paez; G Peng; H Yue; L T H Nguyen; F Niyonsaba
Journal:  Clin Exp Immunol       Date:  2021-02-15       Impact factor: 5.732

4.  Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial.

Authors:  Tessa Niemeyer-van der Kolk; Hein van der Wall; Geretta K Hogendoorn; Rianne Rijneveld; Sascha Luijten; Dirk C J G van Alewijk; Ellen H A van den Munckhof; Marieke L de Kam; Gary L Feiss; Errol P Prens; Jacobus Burggraaf; Robert Rissmann; Martijn B A van Doorn
Journal:  Clin Transl Sci       Date:  2020-05-01       Impact factor: 4.689

Review 5.  Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis.

Authors:  Hai Le Thanh Nguyen; Juan Valentin Trujillo-Paez; Yoshie Umehara; Hainan Yue; Ge Peng; Chanisa Kiatsurayanon; Panjit Chieosilapatham; Pu Song; Ko Okumura; Hideoki Ogawa; Shigaku Ikeda; François Niyonsaba
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

Review 6.  Intractable Itch in Atopic Dermatitis: Causes and Treatments.

Authors:  Yoshie Umehara; Chanisa Kiatsurayanon; Juan Valentin Trujillo-Paez; Panjit Chieosilapatham; Ge Peng; Hainan Yue; Hai Le Thanh Nguyen; Pu Song; Ko Okumura; Hideoki Ogawa; François Niyonsaba
Journal:  Biomedicines       Date:  2021-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.